Your browser doesn't support javascript.
loading
Anterior uveitis for the comprehensive ophthalmologist.
Xie, Jim S; Ocampo, Vanessa; Kaplan, Alexander J.
Afiliación
  • Xie JS; Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
  • Ocampo V; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada; Scarborough Health Network, Rheumatology Department, Scarborough, ON, Canada.
  • Kaplan AJ; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada; Toronto Western Hospital, University Health Network, Toronto, ON, Canada. Electronic address: alexander.kaplan@uhn.ca.
Can J Ophthalmol ; 2024 Aug 08.
Article en En | MEDLINE | ID: mdl-39128830
ABSTRACT
Anterior uveitis presents a diagnostic challenge due to its wide array of etiologies and clinical manifestations. This narrative review aims to equip general ophthalmologists with a comprehensive understanding of anterior uveitis epidemiology, diagnosis, and treatment. Particular emphasis is placed on developing a tailored and stepwise strategy, rather than a one-size-fits-all approach, for the workup and treatment of anterior uveitis. Chest radiography and serologic testing for syphilis, human leukocyte antigen B27, and angiotensin-converting enzyme are appropriate routine investigations in cases of severe, bilateral, recurrent, or chronic anterior uveitis. Additional testing should be guided by clinical findings and regional epidemiology, especially when considering expensive and invasive modalities. Investigations that are obtained in the absence of clinical and epidemiologic orientation are of limited utility and incur significant costs to patients and health care systems. Most cases of anatomically isolated anterior uveitis resolve with topical corticosteroids, but some patients require escalation to systemic immunomodulatory therapy (IMT). IMT should be considered in patients who respond poorly to corticosteroids, develop side effects related to corticosteroids that limit their use, require high doses to maintain disease remission, or have concomitant systemic inflammatory disease. Comprehensive ophthalmologists should feel comfortable comanaging patients that require conventional disease-modifying antirheumatic drugs/antimetabolite therapy (i.e., methotrexate, azathioprine, and mycophenolate mofetil) with rheumatologists and providing guidance on ocular dosing. When uveitis quiescence cannot be achieved despite maximally tolerated antimetabolite therapy, patients should be referred to a uveitis specialist for consultation and consideration of IMT escalation. The timing of uveitis referral may depend on local factors specific to health care jurisdictions.

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Can J Ophthalmol / Can. j. ophthalmol / Canadian journal of ophthalmology Año: 2024 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Can J Ophthalmol / Can. j. ophthalmol / Canadian journal of ophthalmology Año: 2024 Tipo del documento: Article País de afiliación: Canadá